Hypertrophic Scars Therapeutics Pipeline Analysis, Clinical Trials and Developments

According to a new research report “Hypertrophic Scars Therapeutics – Pipeline Analysis- Clinical Trials and Results and Developments" published by Pharma Proff, Hypertrophic scars therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Hypertrophic scar can be defined as a thickened and raised scar that forms at the site where skin is damaged. A hypertrophic scar is an after effect to an injury. This condition occurs when the myofibroblasts produce collagen in excess during repairing process. This can happen when an injury is infected, under an extraordinary pressure, or left to recover without stitches.

Hypertrophic scars can be effectively analyzed by physical examination as they are red and raised at the site of damaged skin and cause itchy sensations. With time, these scars tend to become flat and pale.

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been found that the topical route of administration is non-invasive and easy to use, and ensures high level of patient satisfaction.

Download report sample at: https://www.pharmaproff.com/request-sample/1221

An analysis done for pipeline products demonstrated that RXI-109 and STP-705 are leading product candidates for the treatment of hypertrophic scars. With the approval of these candidates and rising development of other pipeline products will cater the growth of the hypertrophic scar therapeutics market in the next 10 years.

Bristol-Myers Squibb Company, Sirnaomics Inc., Phio Therapeutics Corp., Allergan plc, Sensus Healthcare, Advanced Bio-Technology Inc., OliX Pharmaceuticals Inc., SiSaf Ltd., Juventas Therapeutics Inc., HUGEL Inc., TOPADUR PHARMA AG, Phio Pharmaceuticals Corp., and Lemonex Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of hypertrophic scars.